Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.

This study found that both oral and topical formulations of VISPOTM, a saw palmetto oil, significantly reduced hair fall and increased hair density in subjects with androgenetic alopecia, with no serious adverse effects observed.

In this study, Leonuri Herba alkaloids significantly reduced prostate hyperplasia indicators and improved urinary parameters in hormone-induced model rats.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.

This article reviews current diagnostic and treatment approaches for androgenetic alopecia but reports no new results, focusing on its progression and medical management options.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This review discusses the role of androgens in women's sexual health and highlights the need for further research on androgen replacement therapy to optimize quality of life, but reports no new clinical results.

In this study, higher urethral prostate-specific antigen (urPSA) levels in men after radical prostatectomy were associated with higher androgenic alopecia scores and higher postoperative PSA.

This study found that combining fructose and DHT in rats successfully mimicked the clinical phenotypes of non-lean PCOS, providing a novel rodent model for this condition.

In this study, the researchers identified MJ04, a selective JAK3 inhibitor, as a promising candidate for promoting hair growth, demonstrating efficacy in both animal models and human hair follicle assays with a favorable safety and pharmacokinetic profile.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Combination of minoxidil and finasteride is more effective in increasing hair diameter than minoxidil alone for female-pattern hair loss.

MK-386 reduces sebum DHT levels.

In this study, researchers found no significant differences in serum levels of DHEAs, DHT, and testosterone between female patients with oral lichen planus and healthy controls, suggesting no neuroendocrine etiology linked to the condition.

In this study, researchers found no significant differences in the serum levels of DHEAs, DHT, and testosterone between female patients with oral lichen planus and healthy controls, suggesting no neuroendocrine etiology is associated with this condition.

This study found that prenatal exposure to finasteride in rats led to permanent changes in developmental endpoints like anogenital distance and nipple retention, which were predictive of further reproductive tract malformations.

This study assessed lipid parameters and serum DHT levels in type 2 diabetes patients, but the abstract does not specify the findings about their association.

Both drugs lower DHT levels, with GI198745 being more effective.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

Finasteride significantly reduces DHT levels in male dogs without affecting testosterone levels, suggesting it could be used to treat benign prostatic hypertrophy in dogs weighing 10 to 50 kilograms.

This study observed that androgen levels rise with pubic hair development in Tanner stages, differing by sex and age, with DHEA showing a significant prepubertal increase especially in precocious adrenarche.

This review discusses the enzyme levels involved in dihydrotestosterone formation in androgenetic alopecia patients and reports no new results; the authors suggest these differences may lead to better treatments for men and women.

This study found that higher levels of dihydrotestosterone in the parietal region of the scalp may correlate with the clinical presentation of androgenetic alopecia.

Norplant implants lower some androgen levels but don't significantly change sexual function.

This study found that finasteride decreased plasma dihydrotestosterone levels and altered steroid metabolism, similar to the profile of male pseudohermaphrodites with inherited 5a-reductase deficiency.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This study found that finasteride decreases DHT/T levels more significantly in the vertex scalp hair than in the occipital hair of patients with male pattern baldness.

This study found that finasteride significantly reduced dihydrotestosterone levels but did not provide clear evidence of impaired libido or erectile function compared to placebo in men.

Topical finasteride doesn't reduce DHT levels, hinting at an endocrine role in hair loss.